Brimonidine-montmorillonite hybrid formulation for topical drug delivery to the eye was written by Park, Chun Gwon;Choi, Goeun;Kim, Myung Hun;Kim, Se-Na;Lee, Hanna;Lee, Na Kyeong;Choy, Young Bin;Choy, Jin-Ho. And the article was included in Journal of Materials Chemistry B: Materials for Biology and Medicine in 2020.Recommanded Product: 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate This article mentions the following:
Brimonidine (BMD) is often prescribed as an eye drop to reduce the intraocular pressure (IOP) for glaucoma treatment. However, eye drops are limited by rapid clearance from the preocular surface, and hence a low ocular drug bioavailability. Therefore, in this study, we propose montmorillonite (MMT), as a delivery carrier, hybridized with BMD (BMD-MMT) for topical drug delivery to the eye. The BMD-MMT hybrid was prepared by intercalating the BMD mols. in the interlayer space of the MMT lattice via ion-exchange reaction; it was then formulated with polyvinyl alc. (PVA) to produce a dry tablet (i.e., BMD-MMT@PVA). The BMD-MMT@PVA hybrid drug released BMD in a sustained manner for more than 5 h under in vitro conditions. When the hybrid drug was administered to rabbit eyes in vivo, 43% and 18.5% BMD-MMT still remained on the preocular surface for 10 and 60 min after administration, resp. Thus, the BMD-MMT@PVA hybrid drug exhibited a prolonged decrease in IOP, i.e., for 12 h, which was approx. two times longer than that observed with the com. available BMD eye drop, Alphagan P. In the experiment, the researchers used many compounds, for example, 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5Recommanded Product: 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate).
5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate (cas: 70359-46-5) belongs to quinoxaline derivatives. Quinoxalines have received a significant amount of attention due to their potential use in fighting various pathophysiological conditions like epilepsy, Parkinson鈥檚, and Alzheimer鈥檚 diseases. The parent substance of the group, quinoxaline, results when glyoxal is condensed with 1,2-diaminobenzene. Substituted derivatives arise when 伪-ketonic acids, 伪-chlorketones, 伪-aldehyde alcohols and 伪-ketone alcohols are used in place of diketones.Recommanded Product: 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate
Referemce:
Quinoxaline – Wikipedia,
Quinoxaline | C8H6N2 | ChemSpider